Metabolic abnormalities, antiretroviral therapy and cardiovascular disease in elderly patients with HIV;Alteraciones metabólicas, terapia antirretroviral y enfermedad cardiovascular en adultos mayores portadores de VIH

Arquivos Brasileiros de Cardiologia

Volumn 93, Issue 5, 2009, Pages

  Kramer, Andréa Sebben ^b   Lazzarotto, Alexandre Ramos ^c   Sprinz, Eduardo ^a   Manfroi, Waldomiro Carlos ^a,b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c UNIVERSIDADE FEEVALE   (Brazil)

Author keywords

Aged; Antiretroviral therapy; Cardiovascular diseases; Dyslipidemias; Highly active; HIV AIDS; Lipid metabolism

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ENFUVIRTIDE; FIBRIC ACID DERIVATIVE; FOSAMPRENAVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LAMIVUDINE; LOPINAVIR; METFORMIN; NELFINAVIR; NEVIRAPINE; NICOTINIC ACID; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ACUTE HEART INFARCTION; ANEMIA; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE CARRIER; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; DYSLIPIDEMIA; GLUCOSE INTOLERANCE; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; METABOLIC DISORDER; MITOCHONDRIAL TOXICITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PERIPHERAL NEUROPATHY; RASH; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; AGED; CHEMICALLY INDUCED DISORDER; FEMALE; MALE; METABOLISM; MIDDLE AGED; RISK FACTOR;

AGED; ANTI-RETROVIRAL AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HIV INFECTIONS; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; RISK FACTORS;

EID: 76149105182     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2009001100019     Document Type: Review

References (81)

1. Manavi K. A review on infection with human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol. 2006; 20 (6): 923-40.
2. Paschoal SMP. Epidemiologia do envelhecimento. In: Papaléo Netto M (ed). Gerontologia. São Paulo: Atheneu; 1996. p. 247-61.
3. Ministério da Saúde. Casos de AIDS identificados no Brasil segundo faixa etária. [Acesso em 2008 fev 18]. Disponível em http://www.aids.gov.br/cgi/tabcgi.exe?tabnet/aids.def.
4. Ministério da Saúde. Boletim epidemiológico - AIDS e DST. 2007. [Acesso em 2008 fev 24]. Disponível em http://www.aids.gov.br
5. Secretaria da Saúde do Rio Grande do Sul. Aids: boletim epidemiológico. [Acesso em 26 mar 2008]. Disponível em http://www.saude.rs.gov.br
6. Lazzarotto A, Kramer AS, Hädrich M, Tonin M, Caputo P, Sprinz E. O conhecimento de HIV/AIDS na terceira idade: estudo epidemiológico no Vale do Sinos/Rio Grande do Sul - Brasil. Revista Ciência & Saúde Coletiva. 2008; 13 (6): 1535-40.
7. Melo MR, Gorzoni M, Melo KC, Melo E. Síndrome da imunodeficiência adquirida no idoso. Diagn Tratamento. 2002; 7: 13-7.
8. Casau NC. Perspective on HIV infection and aging: emerging research on the horizon. Clin Infect Dis. 2005; 41: 855-63.
9. El-Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med. 1995; 155: 184-6.
10. Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged ≥50 years compared with younger people in an urban observational cohort. Clin Infect Dis. 2003; 36: 212-8.
11. Ministério da Saúde. Recomendações para terapia anti-retroviral em adultos e adolescentes infectados pelo HIV 2007-2008. [Acesso em 2008 maio 26]. Disponível em http://www.aids.gov.br
12. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV. N Engl J Med. 2006; 354: 251-60.
13. Deeks SG, Volberding P. Antiretroviral therapy for HIV infection: promises and problems. JAMA. 1998; 279: 1343-4.
14. ter Hofstede HJ, Burger DM, Koopmans PP. Antiretroviral therapy in HIV patients: aspects of metabolic complications and mitochondrial toxicity. Neth J Med. 2003; 61: 393-403.
15. Jiménez-Expósito MJ, Mestres CA, Claramonte X, Cartañá R, Josa M, Pomar JL, et al. Mortality and morbidity in HIV-infected patients undergoing coronary artery bypass surgery: a case control study. Rev Esp Cardiol. 2006; 59 (3): 276-9.
16. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, et al. Lopinavir-Ritonavir versus Nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346: 2039-46.
17. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. JAMA. 2002; 288 (2): 222-35.
18. Tuboi SH, Harrison LH, Sprinz E, Albernaz RK, Schechter M. Predictors of virologic failure in HIV-1-infected patients starting highly active antiretroviral therapy in Porto Alegre, Brazil. J Acquir Immunr Defic Syndr. 2005; 40: 324-8.
19. Hajjar L, Calderaro D, Yu PC, Giuliano I, Lima EMO, Barbaro G, et al. Manifestações cardiovasculares em pacientes com infecção pelo Vírus da Imunodeficiência Humana. Arq Bras Cardiol. 2005, 85: 363-77.
20. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, Kotler MN. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med. 2000; 160 (5): 602-8.
21. Milei J, Grana D, Fernández Alonso G, Matturri L. Cardiac involvement in acquired immunodeficiency syndrome: a review to push action. Clin Cardiol. 1998; 21: 465-72.
22. Grinspoon S, Kamin D. Cardiovascular disease in HIV-positive patients. AIDS. 2005; 19: 641-52.
23. Barbaro G. Reviewing the cardiovascular complications of HIV infection after the introduction of highly active antiretroviral therapy. Curr Drug Targets Cardiovasc & Haematol Dis. 2005; 5: 337-43.
24. Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, et al. Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children. AIDS. 2003; 17 (9): 1319-27.
25. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999; 13 (10): F63-F70.
26. Pedro-Botet J, Jericó C, Knobel H, Montero M, Ordoñez-Llanos J, Guelar A, et al. Metabolic syndrome among HIV-infected patients: prevalence, characteristics, and related factors. Diabetes Care. 2005; 28 (1): 132-7.
27. Rader D, Tershakovec AM, Frank I. HIV-related lipodystrophy and related factors. Atherosclerosis. 2004; 174: 1-10.
28. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother. 2006; 57: 4-7.
29. Mouser V. Atherosclerosis and HIV in the highly active antiretroviral therapy era: towards an epidemic of cardiovascular disease? AIDS. 2003; 17 (Suppl 1): S65-S69.
30. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels, the Framingham Study. JAMA. 1986; 256: 2835-8.
31. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989; 79 (1): 8-15.
32. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PW, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996; 276 (7): 544-8.
33. Masiá-Canuto M, Morell EB, Rodero FG. Alteraciones lipídicas y riesgo cardiovascular asociado a la terapia antirretroviral. Enferm Infecc Microbiol Clin. 2006; 24 (10): 637-48.
34. Carr A, Samaras K, Chisholm D, Cooper A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 1998; 352: 1881-3.
35. Barbaro G. Pathogeneses of HIV-associated heart disease. AIDS. 2003; 17: S12-S20.
36. Barbaro G. Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Therapeut. 2006; 13: 248-60.
37. Sociedade Brasileira de Cardiologia. IV Diretriz brasileira sobre dislipidemias e prevenção da aterosclerose. Arq Bras Cardiol. 2007; 88 (supl. I): S2-S19.
38. Bertolami MC. Alterações do metabolismo lipídico no paciente com síndrome metabólica. Rev Soc Cardiol Estado de São Paulo. 2004; 4: 551-6.
39. Machado UF, Schaan BD, Seraphim PM. Transportadores de glicose na síndrome metabólica. Arq Bras Endocrinol Metab. 2006; 50: 177-89.
40. Behrens G, Schmidt R. Lipodystrophy syndrome. In: Hoffmann C, Rockstroh J, Kamps BS. HIV Medicine - 2005. [Accessed from 2006 Apr 14]. Available from: http://www.hivmedicine.com
41. Calza L, Manfredi R, Farneti B, Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int J Antimicrob Agents. 2003; 22 (1): 54-9.
42. Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet. 2000; 356: 1423-30.
43. Barbaro G. Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. Curr HIV Res. 2006; 4 (1): 79-85.
44. Feinglos M, Luna B. Drug-induced hyperglycemia. JAMA. 2001; 286: 1945-8.
45. Valente AMM, Reis AF, Machado DM, Succi RCM, Chacra AR. Alterações metabólicas da síndrome lipodistrófica do HIV. Arq Bras Endocrinol Metab. 2005; 49: 871-81.
46. Noor MA, LoJC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS. 2001; 15 (17): f11-18.
47. Schwarz JM, Lee GA, Park S, Noor MA, Lee J, Wen M, et al. Indinavir increases glucose production in healthy HIV-negative men. AIDS. 2004; 18 (13): 1852-4.
48. Dubé MP. Disorders of glucose metabolism in patients infected with human immunodeficiency virus. Clin Infect Dis. 2000; 31: 1467-75.
49. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999; 13: F63-F70.
50. Bashan N, Ben-Romano R, Rudich A, Török D, Vanounou S, Riesenberg K, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS. 2003; 17 (1): 23-32.
51. Hruz PW, Koster JC, Remedi MS, Qiu H, Nichols CG. HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes. 2003; 52 (7): 1695-700.
52. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS. 2002; 16: 859-63.
53. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem. 2000; 275: 20251-4.
54. Friis-Moller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, et al. Data collection on adverse events of anti-HIV drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003; 349: 1993-2003.
55. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio Monforte A, et al. DAD study group. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD Study. AIDS. 2003; 17: 1179-93.
56. Friis-Moller N, Reiss P, Sabin CA, Weber R, Monforte AA, El-Sadr W, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl Med. 2007; 356: 1723-35.
57. Rickerts V, Brodt H, Staszewski S, Stille W. Incidence of myocardial infarctions in HIV-infected patients between 1983 and 1998: the Frankfurt HIV-cohort study. Eur J Med Res. 2000; 5 (8): 329-33.
58. Klein D, Hurley LB, Quesenberry CP Jr, Sidney S. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection ? J Acquir Immune Defic Syndr. 2002; 30: 471-7.
59. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003, 17: 2479-86.
60. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007, 44 (12): 1625-31.
61. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, et al. An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. Clin Ther. 2003; 25 (9): 2405-18.
62. Bergersen BM, Sandvik L, Bruun JN, Tonstad S. Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects. Eur J Clin Microbiol Infect Dis. 2004; 23: 625-30.
63. De Socio GV, Parruti G, Quirino T, Ricci E, Schillaci G, Adriani B, et al. CISAI study group. Identifyng HIV patients with an unfavorable cardiovascular risk profile in the clinical practice: results from the SIMONE study. J Infect. 2008; 57 (1): 33-40.
64. Triant VA, Lee H, Hadigan C, Grinspoon S. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007; 92 (7): 2506-12.
65. Glass TR, Ungsedhapand C, Wolbers M, Weber R, Vernazza PL, Rickenbach M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med. 2006; 7 (6): 404-10.
66. Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis. 2007; 45 (8): 1074-81.
67. Silverberg MJ, Leyden W, Horberg MA, DeLorenze GN, Klein D, Quesenberry CP Jr. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med. 2007; 167 (7): 684-91.
68. Orlando G, Meraviglia P, Cordier L, Meroni L, Landonio S, Giorgi R, et al. Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients. HIV Med. 2006; 7 (8): 549-57.
69. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003; 33 (4): 506-12.
70. Kamin DS, Grinspoon SK. Cardiovascular disease in HIV-positive patients. AIDS. 2005; 19: 641-52.
71. Dube MP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus infected adults receiving antiretroviral therapy. Clin Infec Dis. 2003; 37: 613-27.
72. Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr. 2005; 38: 115-23.
73. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005; 352: 48-62.
74. National Cholesterol Education Program Executive Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in adults (Adult treatment Panel III). JAMA. 2001; 285: 248-97.
75. Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an international AIDS society - USA panel. J Acquir Immune Defic Syndr. 2002; 31: 257-75.
76. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, Segal Y, Aberg JA, Biaschke T, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002; 16: 569-77.
77. Montessori V, Press N, Harris M, Akagi L, Montaner JS Adverse effects of antiretroviral therapy for HIV infection. CMAJ. 2004; 170 (2): 229-38.
78. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000; 284 (4): 472-7.
79. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, et al. Increased PAI-1 and tPA antigen levels are reduced UIT metformin therapy in HIV-infected patients UIT fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2001; 86 (2): 939-43.
80. Hadigan C, Rabe J, Grinspoon S. Sustained benefits of metformin therapy on markers of cardiovascular risk in human immunodeficiency virus-infected patients UIT fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2002; 87 (10): 4611-5.
81. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004; 350 (12): 1120-34.